Scarica l'app Stockscreener
52.23
0.46%
-0.24
Dopo l'orario di chiusura:
52.35
0.12
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$52.47
Aprire:
$53.03
Volume 24 ore:
1.55M
Relative Volume:
2.25
Capitalizzazione di mercato:
$2.52B
Reddito:
$1.36B
Utile/perdita netta:
$123.81M
Rapporto P/E:
21.67
EPS:
2.41
Flusso di cassa netto:
$20.35M
1 W Prestazione:
-31.38%
1M Prestazione:
-30.84%
6M Prestazione:
-14.81%
1 anno Prestazione:
-30.04%
Intervallo 1D:
$50.68
$53.33
Intervallo di 1 settimana:
$50.68
$76.62
Portata 52W:
$50.68
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Confronta HAE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
52.23 | 2.53B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
131.02 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.64 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.61 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.08 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.93 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Call Transcript - Insider Monkey
Is Haemonetics Corporation meeting your algorithmic filter criteriaDaily Investment Ideas with Market Insight - Newser
I’m Recommending Haemonetics Again, But With Caveats (Ratings Upgrade) (NYSE:HAE) - Seeking Alpha
Understanding Haemonetics (HAE) Reliance on International Revenue - Yahoo Finance
Haemonetics stock rating downgraded by Raymond James on vascular closure slowdown - Investing.com
Haemonetics’ (HAE) “Neutral” Rating Reiterated at JPMorgan Chase & Co. - Defense World
Mizuho Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - Defense World
Haemonetics Corporation stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Haemonetics (NYSE:HAE) Receives “Buy” Rating from Needham & Company LLC - Defense World
Barrington Research Lowers Haemonetics (NYSE:HAE) Price Target to $86.00 - Defense World
Haemonetics (NYSE:HAE) Earns “Buy” Rating from Needham & Company LLC - Defense World
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $62 to $86 - 富途牛牛
Detecting price anomalies in Haemonetics Corporation with AIFree Trade Ready Stock Watch for Short Term - Newser
What makes Haemonetics Corporation stock price move sharplyAI Swing Strategy Signal Forecasting System - Newser
How to escape a deep drawdown in Haemonetics CorporationBuy Point Strategy with Profit Protection - Newser
Haemonetics Reports Q1 Fiscal 2026 Earnings - The Globe and Mail
JP Morgan Downgrades Haemonetics (HAE) - MSN
Haemonetics Corporation stock trendline breakdownFree Breakout Confirmation With Entry Tracker - Newser
Haemonetics Corp Reports Strong Organic Growth Despite Portfolio Transitions - AInvest
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results - Benzinga
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Technical signs of recovery in Haemonetics CorporationSummary of Consistent Growth Stock Picks - Newser
Haemonetics: Fiscal Q1 Earnings Snapshot - Connecticut Post
Haemonetics stock rating cut by JPMorgan on mixed results - Investing.com
Haemonetics (NYSE:HAE) Shares Down 22.1% Following Analyst Downgrade - Defense World
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
Haemonetics Corp (HAE) Analysts Lower Price Target to $68, Maintain "Buy" Rating - AInvest
Analyst Needham Lowers Price Target for Haemonetics (HAE) to $68 - GuruFocus
Haemonetics stock price target lowered to $68 at Needham on competition - Investing.com Canada
Earnings call transcript: Haemonetics beats Q1 2026 earnings, stock drops - Investing.com
Haemonetics Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say - Nasdaq
Haemonetics Corporation Reports Earnings Results for the First Quarter Ended June 28, 2025 - MarketScreener
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Haemonetics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
Haemonetics (HAE) Q1 Revenue Falls 4% - The Motley Fool
Haemonetics Corp Q1 Fiscal 2026 Earnings: Revenue Surpasses Esti - GuruFocus
Haemonetics' Q1 2025 Earnings: Strategic Resilience and Long-Term Value Amid Plasma Challenges - AInvest
Haemonetics Corporation Q1 Fiscal 2026 Results - TradingView
HAEMONETICS CORP SEC 10-Q Report - TradingView
Haemonetics Q1 FY26 Earnings Released Today: Join Live Conference Call for Full Analysis - Stock Titan
Is Haemonetics Corporation stock entering bullish territoryFree Buy Signal Based on Chart Analysis - Newser
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
What makes Haemonetics Corporation stock attractive to long term investorsCapital Protection Strategy With Risk Analysis - Newser
Brokerages Set Haemonetics Corporation (NYSE:HAE) Price Target at $97.30 - Defense World
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Why Haemonetics Corporation stock attracts strong analyst attentionCapital Safe Picks with Consistent Gains - Newser
Analyzing net buyer seller activity in Haemonetics CorporationDownside Control Plan With Support Analysis - Newser
Using data models to predict Haemonetics Corporation stock movementAccurate Forecast System with AI Support - Newser
Leading vs lagging indicators on Haemonetics Corporation performanceFree Chart Driven High Reward Trading Setup - Newser
What drives Haemonetics Corporation stock priceCapitalize on market trends with confidence - Jammu Links News
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):